Bioabsorbable Co-Filler for Cerebrovascular Aneurysms

Abstract

Materials and Methods for delivering materials for filling aneurysms in which the materials comprise a glycosaminoglycan and optionally, contrast media and physiological buffers and in which delivery methods include percutaneous delivery with a balloon catheter or a needle catheter.

What is claimed is: 
     
         1 . A composition comprising a mixture of
 a non-particulate, flowable, non-fibrotic glycosaminoglycan or mucopolysaccharide, and   a sufficient amount of a material comprising contrast media such that the mixture is medically imageable.   
     
     
         2 . The composition of  claim 1  further comprising a physiological buffer. 
     
     
         3 . The composition of  claim 2  further comprising avian protein. 
     
     
         4 . The composition of  claim 2  wherein the glycosaminoglycan or mucopolysaccharide is selected from hyaluronic acid, sodium hyaluronate, chondroitin sulfate, dermatan sulfate, keratan sulfate, or heparin sulfate. 
     
     
         5 . The composition of  claim 2  further comprising blood protein components, blood protein decomposition products, blood cells, blood cell decomposition products, other endogenous compounds, aneurytic tissue components, aneurytic tissue decomposition products, or coil decomposition products. 
     
     
         6 . The composition of  claim 5  wherein the glycosaminoglycan or mucopolysaccharide has a hydrogel nature, has a high viscosity, and is non-thrombogenic. 
     
     
         7 . The composition of  claim 1  wherein the glycosaminoglycan or mucopolysaccharide is selected from hyaluronic acid, sodium hyaluronate, chondroitin sulfate, dermatan sulfate, keratan sulfate, or heparin sulfate. 
     
     
         8 . The composition of  claim 7  wherein the contrast media is selected from metrizamide, iodecimol, ioglucol, ioglucamide, ioglunide, iogulamide, iomeprol, iopentol, iopromide, iosarcol, iosimide, iotasul, ioxilan, iohexyl, ioversol, iopamidol, iotrolan, ioxaglate, iodixanol, iothalamate, ioxithalamate, iodamide, metrizoate, copper-zinc ferrite, nickel-zinc ferrite, manganese-zinc ferrite, zinc ferrite, magnesium ferrite, α-ferric oxide, ferrosoferric oxide, diatrizoate, barium sulfate, diatrizoic acid, metrizoic acid, iotalamic acid, ioxitalamic acid, ioglicic acid, acetrizoic acid, iocarmic acid, methiodal, diodone, ioxaglic acid, iobitridol, iodoxamic acid, iotroxic acid, ioglycamic acid, adipiodone, iobenzamic acid, iopanoic acid, iocetamic acid, sodium iopodate, tyropanoic acid, calcium iopodate, ethyl esters of iodized fatty acids, iopydol, propyliodone, iofendylate, or lipiodol. 
     
     
         9 . The composition of  claim 8  wherein the molecular ratio of glycosaminoglycan or mucopolysaccharide to contrast media ranges from 1.2:1 to 1,000,000:1. 
     
     
         10 . A composition comprising a mixture of
 a non-particulate, flowable, non-fibrotic glycosaminoglycan and   a sufficient amount of a material comprising contrast media such that the mixture is medically imageable and   wherein the contrast media is selected from metrizamide, iodecimol, ioglucol, ioglucamide, ioglunide, iogulamide, iomeprol, iopentol, iopromide, iosarcol, iosimide, iotasul, ioxilan, iohexyl, ioversol, iopamidol, iotrolan, ioxaglate, iodixanol, iothalamate, ioxithalamate, iodamide, metrizoate, copper-zinc ferrite, nickel-zinc ferrite, manganese-zinc ferrite, zinc ferrite, magnesium ferrite, α-ferric oxide, ferrosoferric oxide, diatrizoate, barium sulfate, diatrizoic acid, metrizoic acid, iotalamic acid, ioxitalamic acid, ioglicic acid, acetrizoic acid, iocarmic acid, methiodal, diodone, ioxaglic acid, iobitridol, iodoxamic acid, iotroxic acid, ioglycamic acid, adipiodone, iobenzamic acid, iopanoic acid, iocetamic acid, sodium iopodate, tyropanoic acid, calcium iopodate, ethyl esters of iodized fatty acids, iopydol, propyliodone, iofendylate, or lipiodol.   
     
     
         11 . The composition of  claim 10  wherein the glycosaminoglycan is hyaluronic acid. 
     
     
         12 . The composition of  claim 11  wherein the composition is adapted to migrate out of the aneurysm or break down within the aneurysm and be replaced with endogenous compounds over 7-90 days. 
     
     
         13 . The composition of  claim 12  wherein the hyaluronic acid has a hydrogel nature, has a high viscosity, and is non-thrombogenic. 
     
     
         14 . The composition of  claim 13  wherein the molecular ratio of glycosaminoglycan to contrast media ranges from 1.2:1 to 1,000,000:1. 
     
     
         15 . The composition of  claim 10  wherein the composition is adapted to migrate out of the aneurysm or break down within the aneurysm and be replaced with endogenous compounds over 7-90 days. 
     
     
         16 . The composition of  claim 15  wherein the molecular ratio of glycosaminoglycan to contrast media ranges from 1.2:1 to 1,000,000:1. 
     
     
         17 . A method comprising supplying a mixture of
 a non-particulate, flowable, non-fibrotic glycosaminoglycan or mucopolysaccharide, and   a sufficient amount of a material comprising contrast media such that the mixture is medically imageable, and   delivering the mixture to an aneurytic site in mammalian vasculature.   
     
     
         18 . The method of  claim 17  wherein the glycosaminoglycan or mucopolysaccharide is selected from hyaluronic acid, sodium hyaluronate, chondroitin sulfate, dermatan sulfate, keratan sulfate, or heparin sulfate. 
     
     
         19 . The method of  claim 17  wherein the contrast media is selected from metrizamide, iodecimol, ioglucol, ioglucamide, ioglunide, iogulamide, iomeprol, iopentol, iopromide, iosarcol, iosimide, iotasul, ioxilan, iohexyl, ioversol, iopamidol, iotrolan, ioxaglate, iodixanol, iothalamate, ioxithalamate, iodamide, metrizoate, copper-zinc ferrite, nickel-zinc ferrite, manganese-zinc ferrite, zinc ferrite, magnesium ferrite, α-ferric oxide, ferrosoferric oxide, diatrizoate, barium sulfate, diatrizoic acid, metrizoic acid, iotalamic acid, ioxitalamic acid, ioglicic acid, acetrizoic acid, iocarmic acid, methiodal, diodone, ioxaglic acid, iobitridol, iodoxamic acid, iotroxic acid, ioglycamic acid, adipiodone, iobenzamic acid, iopanoic acid, iocetamic acid, sodium iopodate, tyropanoic acid, calcium iopodate, ethyl esters of iodized fatty acids, iopydol, propyliodone, iofendylate, or lipiodol; and
 the glycosaminoglycan or mucopolysaccharide is selected from hyaluronic acid, sodium hyaluronate, chondroitin sulfate, dermatan sulfate, keratan sulfate, or heparin sulfate. 
 
     
     
         20 . The method of  claim 19  wherein delivering the mixture comprises inserting a needle into the aneurysm or delivering a catheter or needle catheter delivery system device to the aneurytic site and depositing the composition into the aneurysm. 
     
     
         21 . The method of  claim 20  further comprising delivering a coil to the aneurysm before, during, or after delivering the mixture. 
     
     
         22 . The method of  claim 18  wherein delivering the composition comprises inserting a needle into the aneurysm or delivering a catheter or needle catheter delivery system device to the aneurytic site and depositing the composition into the aneurysm. 
     
     
         23 . The method of  claim 22  further comprising delivering a coil to the aneurysm before, during, or after delivering the mixture. 
     
     
         24 . The method of  claim 19  wherein delivering the mixture comprises inserting a needle into the aneurysm or delivering a catheter or needle catheter delivery system device to the aneurytic site and depositing the composition into the aneurysm. 
     
     
         25 . The method of  claim 24  further comprising delivering a coil to the aneurysm before, during, or after delivering the mixture.